The international, prospective glanzmann thrombasthenia registry: Treatment and outcomes in surgical intervention

Man Chiu Poon, Roseline D’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet transfusions. We aimed to evaluate recombinant factor VIIa effectiveness and safety for the treatment and prevention of surgical bleeding in patients, with or without platelet antibodies and/or refractoriness, using data from the Glanzmann Thrombasthenia Registry, an international, multicenter, observational, postmarketing study of rFVIIa. Between 2007 and 2011, 96 patients were treated for 206 surgical procedures (minor 169, major 37). History of platelet antibodies was present in 43 patients, refractoriness in 23, antibodies+refractoriness in 17, while 47 had no confirmed antibodies/refractoriness. Treatments analyzed included antifibrinolytics, recombinant factor VIIa, recombinant factor VIIa+antifibrinolytics, platelets±antifibrinolytics and recombinant factor VIIa+platelets±antifibrinolytics. The most frequent treatment for minor procedures was recombinant factor VIIa+antifibrinolytics (n=65), and for major procedures, recombinant factor VIIa+platelets±antifibrinolytics (n=13). In patients without antibodies/refractoriness, recombinant factor VIIa, either alone or with antifibrinolytics, and platelets±antifibrinolytics were rated 100% effective for minor and major procedures. The effectiveness of treatment for minor procedures in patients with antibodies and refractoriness was 88.9% for recombinant factor VIIa, 100% for recombinant factor VIIa+antifibrinolytics, 66.7% for platelets±antifibrinolytics and 100% for recombinant factor VIIa+platelets±antifibrinolytics. One of four adverse events reported for surgery was considered recombinant factor VIIa-treatment-related (non-fatal thromboembolic event in an adult female receiving recombinant factor VIIa+platelets+antifibrinolytics). For all patients, regardless of platelet antibody or refractoriness status, recombinant factor VIIa, administered with or without platelets (±antifibrinolytics), provided effective hemostasis with a low frequency of adverse events in surgical procedures in Glanzmann thrombasthenia patients. This trial was registered at clinicaltrials.gov identifier: 01476423.

Original languageEnglish
Pages (from-to)1038-1044
Number of pages7
JournalHaematologica
Volume100
Issue number8
DOIs
Publication statusPublished - Aug 5 2015

Fingerprint

Thrombasthenia
Registries
Antifibrinolytic Agents
Blood Platelets
Antibodies
Platelet Transfusion
recombinant FVIIa
Hemorrhage
Minor Surgical Procedures

ASJC Scopus subject areas

  • Hematology

Cite this

Poon, M. C., D’Oiron, R., Zotz, R. B., Bindslev, N., Di Minno, M. N. D., & Di Minno, G. (2015). The international, prospective glanzmann thrombasthenia registry: Treatment and outcomes in surgical intervention. Haematologica, 100(8), 1038-1044. https://doi.org/10.3324/haematol.2014.121384

The international, prospective glanzmann thrombasthenia registry : Treatment and outcomes in surgical intervention. / Poon, Man Chiu; D’Oiron, Roseline; Zotz, Rainer B.; Bindslev, Niels; Di Minno, Matteo Nicola Dario; Di Minno, Giovanni.

In: Haematologica, Vol. 100, No. 8, 05.08.2015, p. 1038-1044.

Research output: Contribution to journalArticle

Poon, MC, D’Oiron, R, Zotz, RB, Bindslev, N, Di Minno, MND & Di Minno, G 2015, 'The international, prospective glanzmann thrombasthenia registry: Treatment and outcomes in surgical intervention', Haematologica, vol. 100, no. 8, pp. 1038-1044. https://doi.org/10.3324/haematol.2014.121384
Poon, Man Chiu ; D’Oiron, Roseline ; Zotz, Rainer B. ; Bindslev, Niels ; Di Minno, Matteo Nicola Dario ; Di Minno, Giovanni. / The international, prospective glanzmann thrombasthenia registry : Treatment and outcomes in surgical intervention. In: Haematologica. 2015 ; Vol. 100, No. 8. pp. 1038-1044.
@article{625085ffeee24ddbb2da1af682a13e2f,
title = "The international, prospective glanzmann thrombasthenia registry: Treatment and outcomes in surgical intervention",
abstract = "Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet transfusions. We aimed to evaluate recombinant factor VIIa effectiveness and safety for the treatment and prevention of surgical bleeding in patients, with or without platelet antibodies and/or refractoriness, using data from the Glanzmann Thrombasthenia Registry, an international, multicenter, observational, postmarketing study of rFVIIa. Between 2007 and 2011, 96 patients were treated for 206 surgical procedures (minor 169, major 37). History of platelet antibodies was present in 43 patients, refractoriness in 23, antibodies+refractoriness in 17, while 47 had no confirmed antibodies/refractoriness. Treatments analyzed included antifibrinolytics, recombinant factor VIIa, recombinant factor VIIa+antifibrinolytics, platelets±antifibrinolytics and recombinant factor VIIa+platelets±antifibrinolytics. The most frequent treatment for minor procedures was recombinant factor VIIa+antifibrinolytics (n=65), and for major procedures, recombinant factor VIIa+platelets±antifibrinolytics (n=13). In patients without antibodies/refractoriness, recombinant factor VIIa, either alone or with antifibrinolytics, and platelets±antifibrinolytics were rated 100{\%} effective for minor and major procedures. The effectiveness of treatment for minor procedures in patients with antibodies and refractoriness was 88.9{\%} for recombinant factor VIIa, 100{\%} for recombinant factor VIIa+antifibrinolytics, 66.7{\%} for platelets±antifibrinolytics and 100{\%} for recombinant factor VIIa+platelets±antifibrinolytics. One of four adverse events reported for surgery was considered recombinant factor VIIa-treatment-related (non-fatal thromboembolic event in an adult female receiving recombinant factor VIIa+platelets+antifibrinolytics). For all patients, regardless of platelet antibody or refractoriness status, recombinant factor VIIa, administered with or without platelets (±antifibrinolytics), provided effective hemostasis with a low frequency of adverse events in surgical procedures in Glanzmann thrombasthenia patients. This trial was registered at clinicaltrials.gov identifier: 01476423.",
author = "Poon, {Man Chiu} and Roseline D’Oiron and Zotz, {Rainer B.} and Niels Bindslev and {Di Minno}, {Matteo Nicola Dario} and {Di Minno}, Giovanni",
year = "2015",
month = "8",
day = "5",
doi = "10.3324/haematol.2014.121384",
language = "English",
volume = "100",
pages = "1038--1044",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - The international, prospective glanzmann thrombasthenia registry

T2 - Treatment and outcomes in surgical intervention

AU - Poon, Man Chiu

AU - D’Oiron, Roseline

AU - Zotz, Rainer B.

AU - Bindslev, Niels

AU - Di Minno, Matteo Nicola Dario

AU - Di Minno, Giovanni

PY - 2015/8/5

Y1 - 2015/8/5

N2 - Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet transfusions. We aimed to evaluate recombinant factor VIIa effectiveness and safety for the treatment and prevention of surgical bleeding in patients, with or without platelet antibodies and/or refractoriness, using data from the Glanzmann Thrombasthenia Registry, an international, multicenter, observational, postmarketing study of rFVIIa. Between 2007 and 2011, 96 patients were treated for 206 surgical procedures (minor 169, major 37). History of platelet antibodies was present in 43 patients, refractoriness in 23, antibodies+refractoriness in 17, while 47 had no confirmed antibodies/refractoriness. Treatments analyzed included antifibrinolytics, recombinant factor VIIa, recombinant factor VIIa+antifibrinolytics, platelets±antifibrinolytics and recombinant factor VIIa+platelets±antifibrinolytics. The most frequent treatment for minor procedures was recombinant factor VIIa+antifibrinolytics (n=65), and for major procedures, recombinant factor VIIa+platelets±antifibrinolytics (n=13). In patients without antibodies/refractoriness, recombinant factor VIIa, either alone or with antifibrinolytics, and platelets±antifibrinolytics were rated 100% effective for minor and major procedures. The effectiveness of treatment for minor procedures in patients with antibodies and refractoriness was 88.9% for recombinant factor VIIa, 100% for recombinant factor VIIa+antifibrinolytics, 66.7% for platelets±antifibrinolytics and 100% for recombinant factor VIIa+platelets±antifibrinolytics. One of four adverse events reported for surgery was considered recombinant factor VIIa-treatment-related (non-fatal thromboembolic event in an adult female receiving recombinant factor VIIa+platelets+antifibrinolytics). For all patients, regardless of platelet antibody or refractoriness status, recombinant factor VIIa, administered with or without platelets (±antifibrinolytics), provided effective hemostasis with a low frequency of adverse events in surgical procedures in Glanzmann thrombasthenia patients. This trial was registered at clinicaltrials.gov identifier: 01476423.

AB - Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet transfusions. We aimed to evaluate recombinant factor VIIa effectiveness and safety for the treatment and prevention of surgical bleeding in patients, with or without platelet antibodies and/or refractoriness, using data from the Glanzmann Thrombasthenia Registry, an international, multicenter, observational, postmarketing study of rFVIIa. Between 2007 and 2011, 96 patients were treated for 206 surgical procedures (minor 169, major 37). History of platelet antibodies was present in 43 patients, refractoriness in 23, antibodies+refractoriness in 17, while 47 had no confirmed antibodies/refractoriness. Treatments analyzed included antifibrinolytics, recombinant factor VIIa, recombinant factor VIIa+antifibrinolytics, platelets±antifibrinolytics and recombinant factor VIIa+platelets±antifibrinolytics. The most frequent treatment for minor procedures was recombinant factor VIIa+antifibrinolytics (n=65), and for major procedures, recombinant factor VIIa+platelets±antifibrinolytics (n=13). In patients without antibodies/refractoriness, recombinant factor VIIa, either alone or with antifibrinolytics, and platelets±antifibrinolytics were rated 100% effective for minor and major procedures. The effectiveness of treatment for minor procedures in patients with antibodies and refractoriness was 88.9% for recombinant factor VIIa, 100% for recombinant factor VIIa+antifibrinolytics, 66.7% for platelets±antifibrinolytics and 100% for recombinant factor VIIa+platelets±antifibrinolytics. One of four adverse events reported for surgery was considered recombinant factor VIIa-treatment-related (non-fatal thromboembolic event in an adult female receiving recombinant factor VIIa+platelets+antifibrinolytics). For all patients, regardless of platelet antibody or refractoriness status, recombinant factor VIIa, administered with or without platelets (±antifibrinolytics), provided effective hemostasis with a low frequency of adverse events in surgical procedures in Glanzmann thrombasthenia patients. This trial was registered at clinicaltrials.gov identifier: 01476423.

UR - http://www.scopus.com/inward/record.url?scp=84931427196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931427196&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.121384

DO - 10.3324/haematol.2014.121384

M3 - Article

C2 - 26001792

AN - SCOPUS:84931427196

VL - 100

SP - 1038

EP - 1044

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -